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doi:10.1016/j.kjms.2012.04.038Abstract In this report, we describe a Taiwanese (Han Chinese) family with Leber’s heredi-
tary optic neuropathy. The family carried a mitochondrial DNA mutation (mtDNA
m.14484T>C ) associated with spontaneous visual improvement. A 15-year-old boy from this
family was diagnosed with Leber’s hereditary optic neuropathy 6 months after losing his vision.
His vision recovered after 8 months of supportive treatment. His mother, older brother, and
two sisters also had the same mutation and had previously experienced vision loss. In this
family, there was no male predominance.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.Introduction
Leber’s hereditary optic neuropathy (LHON) is a maternally
inherited disease caused by a mutation in the mitochondrial
DNA (mtDNA). The majority of LHON cases (90e95%) are
caused by one of three primary mtDNA point mutations at
nucleotide positions 11778, 14484, and 3460 [1e3]. Amongof Ophthalmology, Buddhist
3, Jhong Yang Road, Hualien
.tw (R.-K. Tsai).
vier Taiwan LLC. All rights reservthese mutations, the m.11778G>A mutation is the most
common primary mutation, accounting for 50e70% of LHON
cases [1e3]. In Taiwan, a higher prevalence of the
m.11778G>A mutation (92%) in LHON patients has been
reported, while the m.14484T>C mutation accounts for
approximately 8% of LHON cases [4]. The visual prognosis in
LHON is usually poor, and most patients remain legally
blind. The likelihood of visual recovery is greatest in
patients with the m.14484T>C mutation and lowest in
patients with the m.11778G>A mutation. The vision
recovery rate is intermediate in patients with the
m.3460G>A mutation [1e3,5]. There have been reports of
spontaneous vision improvement in LHON patients;ed.
680 H.-Z. Lin et al.however, to our knowledge, no cases of Taiwanese LHON
families with spontaneous vision improvement have been
reported. In this study, we present a Taiwanese family with
a m.14484T>C mutation who experienced spontaneous
vision improvement.
Case report
The proband of the Taiwanese family was a 15-year-old boy
who had experienced painless, progressive deterioration of
bilateral vision for 6 months without a definite diagnosis.
At the onset, his visual acuity in the left eye was worse than
in the right eye, and his visual acuity progressively deteri-
orated for 6 months. His medical records from the hospitals
where he had received treatment demonstrated that he
had hyperemic discs, impaired color vision, visual field
defects, and a poor waveform on the visual-evoked
potentials at the time of the attack. There were no
abnormal findings upon brain magnetic resonance imaging.
He was referred to our clinic for further management. On
ophthalmologic examination, the best corrected visual
acuity was 0.03 in each eye. The pupillary responses were
normal without a relative afferent pupil defect. The
ophthalmoscopic examination showed a pale optic disc in
both eyes, without peripapillary telangiectatic vessels
(Fig. 1A). A fluorescein angiography examination revealed
no dye leakage around the optic discs in either eye
(Fig. 1B). The patient had no other systemic medical
history. Based on the clinical presentation, LHON was sus-
pected. Whole blood and hair roots were collected for
LHON-associated mtDNA sequencing analysis using the ABI
Prism 3100 Genetic Analyzer (Applied Biosystems, FosterFigure 1. (A) Fundus photographs showed a pale appearanc
(B) Fluorescein angiography demonstrated no dye leakage on eitheCity, CA, USA), which revealed a homoplasmic m.14484T>C
mutation. The patient received supportive treatment with
400 mg of oral pentoxifylline and 10 mg ubidecarenone
twice daily. After 8 months of follow-up, his best corrected
visual acuity improved; his final visual acuity was 0.8 in the
right eye and 0.9 in the left eye.
A pedigree analysis revealed that his biological mother,
older brother, and two older sisters also had a history of
visual impairment (Fig. 2). The family members’ age at
onset of vision loss varied from 5 to 39 years old. The
mother had been treated for optic neuritis at 39 years of
age. Twelve years later, her visual acuity was 0.5 in the
right eye and 0.1 in the left eye. The patient’s older brother
and two sisters had visual dysfunction at the ages of 5, 7,
and 12 years, respectively. Twenty-two years later, the
older brother’s visual acuity was 0.2 in both eyes. The two
sisters had better visual outcomes, with visual acuity of 0.9
and 1.0 in both eyes. DNA sequencing revealed that all four
relatives had the same homoplasmic m.14484T>C mutation
upon DNA sequencing (Table 1).
The approval of the institutional review board was not
available for this investigation. However, this study has
followed the principles outlined in the Declaration of
Helsinki.
Discussion
Patients with LHON suffer from rapid, painless loss of
central vision in one eye, followed by loss of vision in the
other eye within days or months [1e3]. LHON is charac-
terized by the relative preservation of pupillary light reflex
[1,3]. In the acute stage, ophthalmoscopic findings includee in both discs and no peripapillary telangiectatic vessels.
r optic disc.
Figure 2. The pedigree of the proband’s family members with Leber’s hereditary optic neuropathy. A genomic study demon-
strated that all affected family members have the homoplasmic m.14484T>C point mutation.
Spontaneous visual improvement in LHON 681circumpapillary telangiectatic microangiopathy and hyper-
emic optic disc [1e3]. The disc is pseudoedematous due to
swelling of the surrounding nerve fiber layer, but no leakage
is seen on fluorescein angiography [2,3]. During the chronic
phase, which lasts 6 months from the disease onset, the
disc edema resolves, and the disc becomes atrophic and
pale [2,3,5]. The pale discs of the proband indicated that
he had chronic LHON at the time of referral.
Among LHON families, most of carriers are homoplasmic
(86e100%) [6,7]. A higher mutation load is associated with
a higher risk of vision loss. The threshold of heteroplasmy for
the m.11778G>A mutation for LHON expression has been
estimated to be above 60e75% [6,8]. Therefore, the children
of amother with the homoplasmicmutation have the highest
risk of disease expression [3]. In the family presented in our
study, all members carried the m.14484T>C mutation with
a homoplasmic pattern. The load of the mutated gene was
100%, and consequently, the patient and his affected family
members all had a higher phenotypic expression of vision
loss.
Although LHON is caused by an mtDNA mutation with
maternal inheritance, there is a trend of male predomi-
nance. Therefore, the existence of an X-linked modifying
gene has been hypothesized [9]. Recent studies have
identified a region on the X chromosome that contains
a high-risk haplotype associated with a 35-fold increase in
vision loss among patients with the m.11778G>A and
m.14484T>C mutations [2,3]. In two large cohorts of
Caucasians carrying the m.14484T>C mutation, the ratios
of affected males to affected females were 2.1:1 [10] andTable 1 Demographic characteristics of family members with L
Age at onset of vision loss Initial VA (OD/OS)
Mother 39 NA
Sister 1 7 0.02/0.3
Brother 5 NA
Sister 2 12 NA
Patient 14 0.03/0.03
NA Z not available; VA Z visual acuity.8:1 [11], respectively. However, no male predominance has
been reported in the Chinese population. Male/female
ratios of 1:1, 1:1.2, and 1:2 have been reported in three
Chinese pedigrees carrying the m.14484T>C mutation [12].
The ratio of affected males to females was 1:1 in the
current pedigree. Among the mutation types, the lifetime
risk of vision loss is higher in male patients (46% in males
and 11% in females) [1,3]. In this family, the final vision
outcomes in females were better than in males.
Currently, there is no effective treatment for LHON.
Pentoxifylline and ubidecarenone were prescribed to the
patient for supportive treatment. Pentoxifylline has anti-
inflammatory properties and neuroprotective effects [13].
Ubidecarenone is coenzyme Q10, a cofactor that shuttles
electrons from complex I and II to complex III in the
mitochondrial oxidative respiratory chain [14]. Only two
cases of coenzyme Q10 treatment have been reported,
and further investigation is needed to verify its effec-
tiveness in LHON [15,16]. A synthetic short-chain deriva-
tive of coenzyme Q10, idebenone, can restore cellular
adenosine triphosphate levels by bypassing the impaired
complex I [17]. The effectiveness of idebenone for LHON
has been a matter of debate [18e21]. Recently, one
randomized controlled trial found that treatment with
high-dose idebenone (900 mg/day) for 24 weeks had
therapeutic effects in LHON patients with discordant
baseline visual acuities [22]. However, visual recovery was
significantly associated only with the 14484 mutation and
was independent of treatment with idebenone in another
retrospective study [23].eber’s hereditary optic neuropathy.
Time elapsed since first attack Current VA (OD/OS)
12 y 0.5/0.1
21 y 1.0/1.0
22 y 0.2/0.2
10 y 0.9/0.9
14 mo 0.8/0.9
682 H.-Z. Lin et al.The visual outcome was favorable in this family, and
there were some possible explanations. First, patients with
the m.14484T>C mutation had the highest visual recovery
rate among the three primary mutation types (37e50%)
[1e3]. Second, a younger age of disease onset in LHON is
associated with a higher vision recovery rate [2]. The onset
of vision loss in LHON typically occurs between 15 and 35
years of age [2,3]. In the family we present, the age at
onset of visual loss was generally younger, with an average
age of 15.4 years. In the natural course of LHON, visual
recovery usually begins slowly between 6 and 12 months
after disease onset [2,3,5]. The proband was referred to us
6 months after disease onset, and it was possibly just the
timing of visual recovery. We assume that the proband’s
visual recovery is part of the natural course of LHON with
a m.14484T>C mutation.References
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